|
Side Effects & Drug Interactions
ADVERSE REACTIONS
Clinical Studies In clinical studies of up to five years in duration adverse experiences associated with FOSAMAX usually were mild, and generally did not require discontinuation of therapy. Text Continues Below
FOSAMAX has been evaluated for safety in approximately 8000 postmenopausal women in clinical studies. Treatment of osteoporosis Postmenopausal women In two identically designed, three-year, placebo-controlled, double-blind, multicenter studies (United States and Multinational; n= 994), discontinuation of therapy due to any clinical adverse experience occurred in 4.1% of 196 patients treated with FOSAMAX 10 mg/ day and 6.0% of 397 patients treated with placebo. In the Fracture Intervention Trial (n= 6459), discontinuation of therapy due to any clinical adverse experience occurred in 9.1% of 3236 patients treated with FOSAMAX 5 mg/ day for 2 years and 10 mg/ day for either one or two additional years and 10.1% of 3223 patients treated with placebo. Discontinuations due to upper gastrointestinal adverse experiences were: FOSAMAX, 3.2%; placebo, 2.7%. In these study populations, 49-54% had a history of gastrointestinal disorders at baseline and 54-89% used nonsteroidal anti-inflammatory drugs or aspirin at some time during the studies. Adverse experiences from these studies considered by the investigators as possibly, probably, or definitely drug related in 1% of patients treated with either FOSAMAX or placebo are presented in the following table. 
Rarely, rash and erythema have occurred. One patient treated with FOSAMAX (10 mg/ day), who had a history of peptic ulcer disease and gastrectomy and who was taking concomitant aspirin developed an anastomotic ulcer with mild hemorrhage, which was considered drug related. Aspirin and FOSAMAX were discontinued and the patient recovered. Page: 1 | 2 | 3 | 4 | Next >>
|
